

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boyle et al.

Serial No.:

09/718,725

Filed:

November 22, 2000

For:

Osteoprotegerin

Docket No.: A-378CIP2C3

Group Art Unit No.: 1647

Examiner: DeBerry, Regina M.

RECEIVED

DEC 2 6 2002

RESPONSE AND AMENDMENT

TECH CENTER 1600/2900

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

This is in response to the Office Action dated June 19, 2002 in which elected Claims 39-41 are rejected under 35 U.S.C. 112. Reconsideration and withdrawal of the rejections are requested.

12/23/2002 HBLANCO 00000009 010519

09718725

01 FC:1202 02 FC:1203

72.00 CH 280.00 CH

IN THE SPECIFICATION

At page 4, replace lines 29-35, with the following:

Figure 1. A. FASTA analysis of novel EST LORF. Shown is the deduced FRI-1 amino acid sequence aligned to the human TNFR-2 sequence (SEQ ID NO: 169 and 170). B. Profile analysis of the novel EST LORF shown is the deduced FRI-1 amino acid sequence aligned to the TNFR-profile (SEQ ID NO: 171 and 173). C. Structural view of TNFR superfamily indicating region which is homologous to the novel FRI-1.

At page 5, replace lines 1-16, with the following:

Figure 2. Structure and sequence of full length rat OPG gene, a novel member of the TNFR superfamily. A. Map of pMOB-B1.1 insert. Box indicates position of LORF within the cDNA sequence (bold line). Black box indicates signal peptide, and gray ellipses indicate position of cysteine-rich repeat

**EXPRESS MAIL CERTIFICATE** 

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mai indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC